Cantor Fitzgerald Predicts Cabaletta Bio FY2025 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Cabaletta Bio in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($2.19) per share for the year. The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share.

A number of other equities research analysts also recently weighed in on the company. UBS Group initiated coverage on Cabaletta Bio in a research report on Thursday, October 10th. They set a “buy” rating and a $10.00 price objective on the stock. William Blair reaffirmed an “outperform” rating on shares of Cabaletta Bio in a research report on Monday, November 18th. TD Cowen upgraded shares of Cabaletta Bio to a “strong-buy” rating in a research note on Friday, November 29th. HC Wainwright restated a “buy” rating and issued a $25.00 target price on shares of Cabaletta Bio in a research note on Friday, January 17th. Finally, Wells Fargo & Company downgraded Cabaletta Bio from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $12.00 to $6.00 in a research report on Thursday, December 19th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Cabaletta Bio has a consensus rating of “Buy” and an average target price of $24.38.

Cabaletta Bio Trading Down 3.5 %

Shares of NASDAQ CABA opened at $2.50 on Thursday. Cabaletta Bio has a 12-month low of $1.76 and a 12-month high of $26.35. The stock’s fifty day simple moving average is $2.63 and its two-hundred day simple moving average is $4.29. The stock has a market capitalization of $122.20 million, a PE ratio of -1.16 and a beta of 2.46.

Hedge Funds Weigh In On Cabaletta Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Cabaletta Bio during the 3rd quarter valued at about $32,000. Point72 DIFC Ltd purchased a new stake in Cabaletta Bio in the third quarter valued at approximately $33,000. Avanza Fonder AB acquired a new position in Cabaletta Bio in the 4th quarter worth approximately $40,000. China Universal Asset Management Co. Ltd. raised its position in Cabaletta Bio by 65.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,395 shares of the company’s stock worth $44,000 after buying an additional 3,724 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in Cabaletta Bio during the 3rd quarter valued at approximately $67,000.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.